ASPA rs1057516995: Understanding Canavan Disease Carrier Status
The rs1057516995 variant is a genetic change located within the ASPA gene, which is associated with carrier status for Canavan disease. Individuals who carry this variant possess one altered copy of the gene, which is a condition typically inherited in an autosomal recessive pattern.
What each genotype means
Typical ASPA genotype
This genotype represents the common, non-pathogenic state for this specific variant. Individuals with this result do not carry this specific mutation associated with Canavan disease.
This is the most common genotype observed in the general population.
Canavan disease carrier
This genotype indicates you are a carrier of a mutation associated with Canavan disease. Carriers are typically asymptomatic and are not at risk of developing the disorder, though you should consult with a genetic counselor regarding reproductive risks.
This genotype is rare in the general population, though carrier frequencies vary significantly by ancestry.
Potential Canavan disease risk
This genotype is associated with the presence of biallelic mutations linked to Canavan disease. If you have received this result, it is important to discuss these findings with a medical professional or clinical geneticist for appropriate diagnostic follow-up.
This genotype is extremely rare in the general population.
Understanding the rs1057516995 Variant
The rs1057516995 variant is a specific single nucleotide polymorphism (SNP) found on chromosome 17. In the context of genetic testing, it is identified as a marker associated with Canavan disease. Genetic variants like this represent small changes in the DNA sequence that can alter the function of a gene. Because Canavan disease is an autosomal recessive condition, an individual must typically inherit two copies of a pathogenic variant—one from each parent—to manifest the disease. A person with only one copy of a pathogenic variant is considered a carrier. Carriers generally do not show symptoms of the disease themselves but can pass the variant to their children. Understanding this variant requires looking at its position within the ASPA gene, which provides instructions for producing the enzyme aspartoacylase.
The Role of the ASPA Gene
The ASPA gene is responsible for encoding the enzyme aspartoacylase. This enzyme plays a critical role in the brain by breaking down a substance called N-acetyl-aspartate (NAA). When the ASPA gene contains pathogenic mutations, the production or function of aspartoacylase is significantly reduced or lost. This leads to an accumulation of NAA in the brain, which is toxic to the myelin sheath—the protective covering of nerve fibers. The resulting damage, known as leukodystrophy, causes the white matter of the brain to degenerate, leading to the severe neurological symptoms characteristic of Canavan disease. Because the enzyme is essential for maintaining healthy brain tissue, variants that disrupt its function are the primary focus of clinical research and carrier screening programs aimed at identifying families at risk for this condition.
Research and Clinical Significance
Research into the ASPA gene has identified numerous variants that contribute to Canavan disease. While certain founder mutations are well-documented in specific populations, such as the Ashkenazi Jewish community, other variants like rs1057516995 are also monitored in clinical settings. The evidence strength for this variant as a carrier marker is considered moderate, meaning it is recognized in clinical databases as having potential significance for carrier screening. It is important to note that clinical laboratories often focus on a limited set of common mutations when performing standard carrier screening. Therefore, the absence of this specific variant in a standard panel does not necessarily rule out carrier status for other, less common mutations. Clinical interpretation of such variants is complex and relies on ongoing genomic research to determine the exact impact of each specific DNA change on enzyme activity.
Population Frequency and Prevalence
Canavan disease is a rare condition, but its carrier frequency varies significantly across different ethnic groups. In the Ashkenazi Jewish population, the carrier frequency is estimated to be approximately 1 in 40 to 1 in 82. In the general population, the frequency is generally lower, though exact numbers can be difficult to determine due to limited global testing data. The rs1057516995 variant is considered rare. Because many population databases are still expanding, the full distribution of this variant across diverse ancestries remains an area of active study. Genetic counselors often use these frequency statistics to help individuals understand their personal risk profile, emphasizing that carrier status is a common occurrence for many recessive conditions and does not imply that an individual has the disease.
Navigating Genetic Information
If you have received information regarding your status for the rs1057516995 variant, it is essential to understand what this means for your health and family planning. Being a carrier is not a diagnosis of a disease; it simply means you carry one copy of a variant that could potentially be passed to offspring. If you are concerned about your carrier status or family history, the most appropriate step is to consult with a certified genetic counselor or a medical professional. They can provide context based on your specific results, discuss the limitations of current testing, and explain the implications for reproductive health. Never use genetic data to make medical decisions without professional guidance. Genetic information is a tool for awareness and informed decision-making, and a clinician can help you interpret these findings accurately within the context of your overall health.
How common is this variant?
The rs1057516995 variant is classified as rare in the general population, with specific frequency data varying by ancestry and database reporting.
Frequently asked questions
What is a carrier of Canavan disease?
A carrier of Canavan disease has one altered copy of the ASPA gene and one normal copy. Carriers do not have the disease but can pass the altered gene to their children.
Does having this variant mean I have Canavan disease?
No, being a carrier does not mean you have the disease. Canavan disease is an autosomal recessive condition, meaning it typically requires two altered copies of the gene to manifest.
Should I be tested for Canavan disease?
Carrier screening is often recommended for individuals with a family history of the disease or those from populations with a higher known carrier frequency. Discuss your personal and family history with a genetic counselor to determine if testing is appropriate for you.
Where can I find more information about my genetic results?
You should consult with a healthcare provider or a board-certified genetic counselor. They can interpret your specific results and provide guidance based on your medical history.
Sources & further reading
Educational information only, last refreshed 10/11/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1057516995?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in ASPA
This variant is associated with carrier status for Canavan disease, a rare neurological disorder.
Pathogenic missense variant (p.Glu285Ala / E285A) causing aspartoacylase deficiency and carrier status for autosomal recessive Canavan disease.
This variant is identified as a carrier mutation for Canavan disease, a rare neurodegenerative disorder.
Common pathogenic nonsense mutation (p.Tyr231Ter / p.Y231X) in ASPA underlying Canavan disease.
Severe pathogenic ASPA nonsense mutation (p.Tyr231Ter) responsible for Canavan disease in reproductive carrier screening.
Pathogenic ASPA missense variant (p.Glu285Ala) causing aspartoacylase deficiency (Canavan disease), standardly tested in preconception carrier panels.